These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25703583)

  • 1. Bevacizumab: A dose review.
    Falk AT; Barrière J; François E; Follana P
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):311-22. PubMed ID: 25703583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in the treatment of metastatic colorectal cancer.
    Caprioni F; Fornarini G
    Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small reduction in quality of life seen with bevacizumab maintenance in patients with ovarian cancer.
    Barton MK
    CA Cancer J Clin; 2013; 63(4):219-20. PubMed ID: 23733586
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Success of bevacizumab trials raises questions for future studies.
    Tuma RS
    J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
    [No Abstract]   [Full Text] [Related]  

  • 9. Bevacizumab in colorectal cancer: current and future directions.
    Yeung Y; Tebbutt NC
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1263-73. PubMed ID: 23113577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technology evaluation: bevacizumab, Genentech/Roche.
    Salgaller ML
    Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
    Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
    Los M; Roodhart JM; Voest EE
    Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular imaging of antiangiogenic agents.
    Rehman S; Jayson GC
    Oncologist; 2005 Feb; 10(2):92-103. PubMed ID: 15709211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
    Marco S; Tomasini P; Greillier L; Barlesi F
    Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metastatic colorectal carcinoma: bevacizumab extends total survival].
    Pflege Z; 2013 Apr; 66(4):252. PubMed ID: 23634556
    [No Abstract]   [Full Text] [Related]  

  • 17. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H; Saini S
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab: current updates in treatment.
    Van Meter ME; Kim ES
    Curr Opin Oncol; 2010 Nov; 22(6):586-91. PubMed ID: 20811277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.
    Saif MW; Merritt J; Robbins J; Stewart J; Schupp J
    Clin Colorectal Cancer; 2006 Sep; 6(3):229-34. PubMed ID: 17026795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.